Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.68 |
| ▸ | REN | P00797 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | F2 | P00734 | 1/20 | 0.68 |
| ▸ | LTA4H | P09960 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | PEPD | P12955 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.68 |
| ▸ | HRH1 | P35367 | 1/20 | 0.68 |
| ▸ | THPO | P40225 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.68 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL967588 | 1.00 | ACE (0.68) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL17323620 | 1.00 | ACE (0.68) | ACERENLMNAHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL6026723 | 0.98 | ACE (0.66) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL16371458 | 0.94 | ACE (0.61) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL17323636 | 0.94 | ACE (0.61) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL17323637 | 0.94 | ACE (0.61) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL6782714 | 0.89 | ACE (0.68) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL6782708 | 0.89 | ACE (0.68) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL19083734 | 0.88 | ACE (0.53) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL17323626 | 0.88 | ACE (0.53) | ACERENLMNAHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101575363-B | The synthetic method of Aplidine and new antitumoral derivatives and preparation and application thereof | PHARMA MAR, S. A. (ES) | 2016-01-27 | — | — | CN | claimed |
| EP-1294747-B1 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR SA (ES) | 2008-04-30 | — | — | EP | claimed |
| US-20040097413-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2004-05-20 | — | — | US | claimed |
| EP-1294747-A2 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR, S.A. (ES) | 2003-03-26 | — | — | EP | claimed |
| WO-2002002596-A2 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR, S.A. (ES) | 2002-01-10 | — | — | WO | claimed |
| JP-1246257-A | — | — | None | — | — | JP | disclosed |
| US-12583835-B2 | Crystal form of nitroxoline prodrug, pharmaceutical composition containing same, and preparation method therefor and application thereof | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4129983-B1 | CRYSTAL FORM OF NITROXOLINE PRODRUG, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGSU YAHONG MEDITECH CO LTD (CN) | 2024-12-25 | — | — | EP | disclosed |
| CN-115697970-B | Preparation method of aromatic ether compound | 江苏亚虹医药科技股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-115427397-B | Crystal form of nitroquinoline prodrug, pharmaceutical composition containing crystal form, preparation method and application of pharmaceutical composition | 江苏亚虹医药科技股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2006134591-A2 | USE OF ALLYLMERCAPTOCAPTOPRIL FOR TREATING OR PREVENTING OBESITY AND OBESITY RELATED DISEASES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2006-12-21 | — | — | WO | disclosed |
| US-20040097413-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2004-05-20 | — | — | US | disclosed |
| EP-1294747-A2 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR, S.A. (ES) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002002596-A2 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR, S.A. (ES) | 2002-01-10 | — | — | WO | disclosed |
| US-6156724-A | Uses of didemnins as immunomodulating agents | PHARMA MAR, S.A. (ES) | 2000-12-05 | — | — | US | disclosed |
| US-5294603-A | Pharmaceutical compositions containing didemnins | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1994-03-15 | — | — | US | disclosed |
| US-5202443-A | PROCESS FOR PREPARING 1-(2S)-3-MERCAPTO-METHYL-1-OXOPROPYL)-L-PROLINE | EGIS GYOGYSZERGYAR (HU) | 1993-04-13 | — | — | US | disclosed |
| JP-H01246257-A | PRODUCTION OF 3-THIOPROPIONIC ACID DERIVATIVE | UNIV MIAMI | 1989-10-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097413-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, PML, APLNR | ACE 2944/4885REN 3997/4885LMNA 2193/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ACE 485/4885REN 2518/4885LMNA 1681/4885 |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | ACE 206/4885REN 2661/4885LMNA 4438/4885 |
| US-12583835-B2 | Crystal form of nitroxoline prodrug, pharmaceutical composition containing same, and preparation method therefor and application thereof | CYP4B1, NOTUM, CYP1B1 | ACE 2053/4885REN 2266/4885LMNA 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.